Financing ·
On September 16, 2026, Teva Pharmaceutical Industries Limited issued $3.2 billion in aggregate principal amount of USD…
TEVATeva Pharmaceutical Industries Ltd
On September 16, 2026, Teva Pharmaceutical Industries Limited issued $3.2 billion in aggregate principal amount of USD Senior Notes and €1.5 billion in Euro Senior Notes through its wholly owned subsidiaries. The issuance includes €1 billion of 4.250% notes due 2033, €500 million of 4.625% notes due 2036, $1 billion each of 5.500% notes due 2034 and 5.750% notes due 2037, and $1.2 billion of 5.250% notes due 2032. Teva intends to use the net proceeds primarily to fund conditional redemptions of existing debt, including all outstanding 6.750% notes due 2028, 7.875% and 7.375% sustainability-linked notes due 2029, up to $450 million of 4.750% notes due 2027, and reduced redemptions of 4.375% notes due 2030 and 8.125% USD sustainability-linked notes due 2031. The company operates in the pharmaceutical industry.